Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Retained Earnings (2021 - 2025)

Krystal Biotech's Retained Earnings history spans 5 years, with the latest figure at $24.2 million for Q4 2025.

  • For Q4 2025, Retained Earnings rose 113.39% year-over-year to $24.2 million; the TTM value through Dec 2025 reached $24.2 million, up 113.39%, while the annual FY2025 figure was $24.2 million, 113.39% up from the prior year.
  • Retained Earnings for Q4 2025 was $24.2 million at Krystal Biotech, up from $1.1 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $24.2 million in Q4 2025 and bottomed at -$359.3 million in Q2 2023.
  • The 5-year median for Retained Earnings is -$105.0 million (2021), against an average of -$122.7 million.
  • The largest annual shift saw Retained Earnings tumbled 1776378.57% in 2022 before it skyrocketed 113.39% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$163000.0 in 2021, then crashed by 346.63% to -$728000.0 in 2022, then tumbled by 36964.15% to -$269.8 million in 2023, then surged by 33.04% to -$180.7 million in 2024, then surged by 113.39% to $24.2 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Retained Earnings are $24.2 million (Q4 2025), $1.1 million (Q3 2025), and -$106.6 million (Q2 2025).